Grifols, S.A..
GRFS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Grifols, S.A. is a global healthcare company specializing in plasma-derived therapies. It operates through three main divisions: Bioscience, Diagnostic, and Hospital. The Bioscience division focuses on researching, developing, manufacturing, and marketing plasma-derived protein therapies. These ther...Show More
Better Health for All
-40
Grifols' core business is dedicated to developing, producing, and marketing plasma-derived therapies and diagnostic products for rare, chronic, and life-threatening conditions across therapeutic areas like immunology, hematology, and neurology, indicating its product portfolio delivers exceptional health benefits.
1
The company received the highest possible score from S&P Global for its sustainability reporting and ethical marketing, and an EcoVadis Ethics score of 81 out of 100, demonstrating industry-leading risk transparency.
2
Grifols collects extensive consumer health data, has a dedicated privacy policy, commits to GDPR compliance, and adopts safeguards for international data transfers, indicating industry-leading data protection.
3
However, the company's adverse events rate of 30-40 per million users, as per its S&P Global CSA score of 70, indicates proactive safety monitoring but still a notable rate of incidents.
4
Grifols' commitment to research and innovation is noted, but no specific percentage of R&D budget allocated to health improvement is provided.
5
The company's environmental score of 92/100 from EcoVadis and commitment to a low-carbon economy suggest limited health-harming externalities.
6
Grifols has a Social-Action and Community-Investment Policy and manages grants and donations to patient associations, but no specific funding percentage or reach is detailed.
7
The company has a Mental Health policy, but no details on programs or funding are available.
8
Grifols uses personal data for research and development and provides biological supplies for clinical trials, but the processing of special categories of personal data is based on legal claims or public interest, suggesting a basic ethical framework.
9
Grifols organizes educational activities and initiatives, but no specific investment or reach is detailed.
10
Fair Money & Economic Opportunity
0
Grifols, S.A. is a global healthcare company specializing in plasma-derived therapies, diagnostics, and hospital products.
1
The company's core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions or companies offering consumer financial services, are not applicable. Evidence regarding pricing relates to healthcare products, not financial products.
2
Information on geographic reach pertains to plasma donation centers, not financial service access points.
3
Corporate financial data, such as the debt-to-equity ratio,
4
does not reflect customer debt burden. Educational grants are for scientific and healthcare issues, not financial literacy.
5
Commitments to UN SDGs are general and do not translate to specific financial inclusion programs or a loan book.
6
As such, there is no evidence to score Grifols against these financial services-specific metrics.
Fair Pay & Worker Respect
-20
Grifols reported a voluntary employee turnover rate of 32% in 2019, which is attributed to a high proportion of entry-level positions in donor centers.
1
The company has one recorded employment-related offense, a $41,775 penalty in 2012 for a Family and Medical Leave Act violation, and one workplace safety or health violation in 2021 with a $5,750 penalty.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Grifols, S.A. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-30
Grifols was fined €1,000,000 by Spain's National Securities Market Commission (CNMV) in July 2025 for inaccurate and untruthful data in consolidated annual financial reports for 2021, 2022, and 2023, and for presenting misleading information related to alternative performance measures.
1
The company admitted to improper accounting and announced restatements related to its joint venture Biotek America LLC and its stake in Shanghai RAAS Blood Products Co. Limited.
2
These restatements included a €38 million negative adjustment to reserves for 2021-2023, an overstatement of net income by €14 million and EBITDA by €12 million for the first half of 2023, and a €457 million writedown on equity due to incorrect accounting for its SRAAS stake.
3
The CNMV also found deficiencies in the level of detail provided in Grifols' financial reports.
4
Grifols has a whistleblowing system, the 'Grifols Ethics Line,' which allows anonymous reporting where permitted by local law and prohibits retaliation.
5
An Anti-Corruption Policy, approved by the Board in April 2025, provides guidance on appropriate standards of conduct for interactions with government officials and other private individuals.
6
Kind to Animals
0
No specific, concrete data points were found in the provided articles to assess Grifols, S.A. against the 'Kind to Animals' ethical value. Information regarding cruelty-free certifications, alternative testing methods, humane certifications for animal operations, wildlife conservation impact, ethical input substitution, supplier audits for animal welfare, cage-free sourcing, animal testing policy, animal testing volume, R&D investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement was not available.
1
No War, No Weapons
0
No evidence available to assess Grifols, S.A. on No War, No Weapons.
Planet-Friendly Business
-40
Grifols reported total greenhouse gas emissions of 1,231,771 tCO2e in 2024, with Scope 3 emissions increasing by 11% last year.
1
The company has SBTi-validated targets to reduce absolute Scope 1 and 2 GHG emissions by 42% and Scope 3 emissions by 25% by 2030 from a 2022 base year, aligning with a 1.5 degrees Celsius pathway.
2
Grifols sources 44.6% of its total electricity consumption from renewable energy.
3
The company has a waste diversion rate of 99% and has maintained Zero Waste to Landfill Gold Status for 7 consecutive years.
4
Grifols owns over 300 acres of protected forest in Clayton, N.C., which has GOLD conservation certification.
5
The company was penalized $156,546 by the EPA in 2004 for hazardous waste violations from 2002.
6
Grifols has a net-zero emissions target for Scope 1 and 2 by 2050.
7
The company follows the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD).
8
Respect for Cultures & Communities
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'. While articles mention general sustainability recognitions, ESG scores, and the existence of policies or partnerships, they lack the concrete numbers, percentages, or specific outcomes required by the rubric's thresholds for scoring.
Safe & Smart Tech
-50
Grifols faces a lawsuit, filed in October 2022, by 54,000 Illinois blood donors alleging a breach of data protection regulations and unauthorized data use.
1
The company is ISO 27001 certified, indicating a high level of accreditation for data security.
2
Grifols states that connections and communications across information systems may be encrypted, and its SRC technology offers high levels of security and encryption.
3
The company has established 10 principles for responsible AI use, including transparency, responsibility, and security, and states that automated decisions are not taken based on profiling activities.
4
Grifols implements monitoring mechanisms for AI systems to identify and mitigate potential legal and ethical risks, and promotes understanding and clarity on the full lifecycle of AI systems.
5
The company outlines data protection rights for users, including access, rectification, erasure, objection, portability, restriction of processing, and withdrawal of consent.
6
Grifols states it retains personal data only for the time strictly necessary for the fulfillment of purposes and assesses security updates meticulously before release.
7
Grifols is committed to complying with GDPR and other applicable data protection regulations in each country, and has a Human Rights Policy and publishes a Human Rights Due Diligence Report.
8
Zero Waste & Sustainable Products
-50
Grifols has implemented several waste reduction initiatives, including an annual 'dumpster dive' for sorting recyclable materials, partnerships for processing polyethylene glycol and diatomaceous earth (over 1,000,000 pounds per month combined), sending organic material to composting, and waste to an energy company for fuel.
1
Diatomaceous earth, previously incinerated as medical waste, is now processed into a fertilizer.
2
The company conducts annual waste audits through its 'dumpster dive' initiative.
3
Grifols' Clayton, N.C. site has been certified as a 'Zero Waste to Landfill' gold location by UL for four consecutive years, diverting over 99% of waste from landfill at that specific site.
4
The company has not reported any waste disposal violations in the past three years.
5
Grifols has a company-wide target to achieve zero waste to landfill by the end of the current year.
6
The company sends 15,000 pounds of single-use gowns/coverings back to the manufacturer, but a percentage reduction from a baseline year is not quantified.
7